Bloomberg: Athenahealth has five potential bidders

Athenahealth, a network-enabled services company for hospitals and ambulatory clients, has bids from at least five entities, according to a report from Bloomberg. The bidders include Bain Capital, Hellman and Friedman, Clayton, Dubiliar & Rice and TPG.

Elliott Management Corp., which currently owns 9 percent of Athenahealth, is also reportedly considering a bid, according to Bloomberg.

The potential sale of Athenahealth comes after its CEO Jonathan Bush announced he was leaving the company in June after admitting to domestic violence allegations against his former wife.

Final bids are due by the end of the month for the company, though Elliott previously said in May it was prepared to make an offer for $160 per share—above the reported new bids of $135 per share. That previous deal was rumored to be worth around $7 billion.

See the full story below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.